157 related articles for article (PubMed ID: 12173299)
1. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study.
Eibl N; Spatz M; Fischer GF; Mayr WR; Samstag A; Wolf HM; Schernthaner G; Eibl MM
Clin Immunol; 2002 Jun; 103(3 Pt 1):249-59. PubMed ID: 12173299
[TBL] [Abstract][Full Text] [Related]
2. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells.
Spatz M; Eibl N; Hink S; Wolf HM; Fischer GF; Mayr WR; Schernthaner G; Eibl MM
Cell Immunol; 2003 Jan; 221(1):15-26. PubMed ID: 12742378
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes.
Kroon FP; van Dissel JT; de Jong JC; van Furth R
AIDS; 1994 Apr; 8(4):469-76. PubMed ID: 7912086
[TBL] [Abstract][Full Text] [Related]
4. Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV.
Talesnik E; Vial PA; Labarca J; Méndez C; Soza X
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):471-7. PubMed ID: 9859960
[TBL] [Abstract][Full Text] [Related]
5. Generation of antigen-specific CD4+ T cell lines from naive precursors.
Mehta-Damani A; Markowicz S; Engleman EG
Eur J Immunol; 1995 May; 25(5):1206-11. PubMed ID: 7774624
[TBL] [Abstract][Full Text] [Related]
6. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.
Rabian C; Tschöpe I; Lesprit P; Katlama C; Molina JM; Meynard JL; Delfraissy JF; Chêne G; Lévy Y;
Clin Infect Dis; 2010 Apr; 50(8):1174-83. PubMed ID: 20210645
[TBL] [Abstract][Full Text] [Related]
7. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.
Gilliet M; Kleinhans M; Lantelme E; Schadendorf D; Burg G; Nestle FO
Blood; 2003 Jul; 102(1):36-42. PubMed ID: 12560234
[TBL] [Abstract][Full Text] [Related]
8. Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells.
Fagnoni FF; Takamizawa M; Godfrey WR; Rivas A; Azuma M; Okumura K; Engleman EG
Immunology; 1995 Jul; 85(3):467-74. PubMed ID: 7558137
[TBL] [Abstract][Full Text] [Related]
9. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
10. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters.
Janoff EN; Tasker SA; Stevenson M; Rubins JB; O'Brien J; Utz G; Weiss P; Hall FW; Wallace MR
AIDS Res Hum Retroviruses; 1999 Jun; 15(9):837-45. PubMed ID: 10381172
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.
Tichmann-Schumann I; Soemantri P; Behre U; Disselhoff J; Mahler H; Maechler G; Sänger R; Jacquet JM; Schuerman L
Pediatr Infect Dis J; 2005 Jan; 24(1):70-7. PubMed ID: 15665713
[TBL] [Abstract][Full Text] [Related]
13. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus.
Kroon FP; van Dissel JT; Labadie J; van Loon AM; van Furth R
Clin Infect Dis; 1995 Nov; 21(5):1197-203. PubMed ID: 8589143
[TBL] [Abstract][Full Text] [Related]
14. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
Valdez H; Smith KY; Landay A; Connick E; Kuritzkes DR; Kessler H; Fox L; Spritzler J; Roe J; Lederman MB; Lederman HM; Evans TG; Heath-Chiozzi M; Lederman MM
AIDS; 2000 Jan; 14(1):11-21. PubMed ID: 10714563
[TBL] [Abstract][Full Text] [Related]
15. Impaired T-cell priming and proliferation in cats infected with feline immunodeficiency virus.
Bishop SA; Williams NA; Gruffydd-Jones TJ; Harbour DA; Stokes CR
AIDS; 1992 Mar; 6(3):287-93. PubMed ID: 1348945
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.
Nordøy T; Husebekk A; Aaberge IS; Jenum PA; Samdal HH; Flugsrud LB; Kristoffersen AC; Holte H; Kvaløy S; Kolstad A
Bone Marrow Transplant; 2001 Oct; 28(7):681-7. PubMed ID: 11704791
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.
Dagan R; Melamed R; Zamir O; Leroy O
Pediatr Infect Dis J; 1997 Nov; 16(11):1053-9. PubMed ID: 9384339
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
20. The immune response to booster vaccination against diphtheria toxin at age 18-21 years.
Nahum E; Lerman Y; Cohen D; Salpon R; Danon YL
Isr J Med Sci; 1994 Aug; 30(8):600-3. PubMed ID: 8045740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
